The shares of Rossari Biotech Limited slipped over 3 per cent intraday on Wednesday owing to general weakness in the market and on profit-booking. The company’s Board of Directors has approved the issuance of 30.12 lakh equity shares on a preferential basis aggregating to nearly ₹300 crore.
At 11:43 am, it was trading at ₹1072.95 on the BSE, down ₹39.50 or 3.55 per cent. It opened at ₹1104.10 as against the previous close of ₹1112.45. It hit an intraday high of ₹1104.10 and an intraday low of ₹1056.80.
On the NSE, it was quoting ₹1,072.55 per share, down ₹38.75 or 3.49 per cent.
Rossari Biotech’s board on Tuesday approved the issuance of up to 30,12,046 equity shares of the face value of ₹ 2/- each, on a preferential basis at ₹996 a share to SBI Mutual Fund, Ramesh Siyani, Arpit Kbandelwal, Malabar Select Fund, Malabar India Fund, Malabar Value Fund and India Acom Fund. Through the issue, the company has raised nearly ₹300 crore.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.